Global Blood Therapeutics, Inc. - Common Stock (NQ:GBT)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Global Blood Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay ↗

July 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,...

Via Benzinga

Global Blood Therapeutics: Return On Capital Employed Insights ↗

July 01, 2021

During Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $39.04 million. Despite a 20.83% in earnings, the company posted a loss of $71.03 million. Global Blood...

Via Benzinga

Why Global Blood Therapeutics Moved Higher Wednesday ↗

July 01, 2021

The pharmaceutical company, which specializes in therapies to fight sickle cell disease, rose nearly 8% on Wednesday.

Via The Motley Fool

Earnings Scheduled For May 5, 2021 ↗

May 05, 2021

Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street ↗

July 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...

Via Benzinga

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study ↗

July 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:...

Via Benzinga

Topics Stocks

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗

July 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

June 30, 2021

During Wednesday's morning session, 29 stocks hit new 52-week lows. Points of Interest: The largest company by market cap to set a new 52-week low was CoStar Gr (...

Via Benzinga

Looking Into Global Blood Therapeutics's Return On Capital Employed ↗

June 30, 2021

In Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $39.04 million. Earnings were up 20.83%, but Global Blood Therapeutics still reported an overall loss of $71.03...

Via Benzinga

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs ↗

June 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 28, 2021

Gainers Intellia Therapeutics (NASDAQ:NTLA

Via Benzinga

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout ↗

June 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

June 28, 2021

Before 10 a.m. ET on Monday, 7 stocks hit new 52-week lows. Noteworthy Mentions: The largest company in terms of market cap to set a new 52-week low was CoStar Gr (...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021 ↗

June 28, 2021

Upgrades For Toll Brothers Inc (NYSE:

Via Benzinga

14 Biotech Stocks To Watch Over The Next 6 Months ↗

June 23, 2021

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:...

Via Benzinga

The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗

June 07, 2021

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...

Via Benzinga

Vaccine Stocks Call For Billions In Sales Even As Covid Resisters Dig In: IBD/TIPP Poll ↗

June 04, 2021

The number of people resistant to receiving a Covid vaccine didn't budget in May, according to the IBD/TIPP Poll. But vaccine stocks aren't sweating it, experts say.

Via Investor's Business Daily

Global Blood Therapeutics Q1 Earnings Miss Estimates On Disappointing Sales For Its Sickle-Cell Disease Drug ↗

May 06, 2021

Global Blood Therapeutics Inc (NASDAQ: GBT) reported a Q1 EPS loss of ($1.21) wider than the anticipated loss estimate of $1.01. Q1 sales of $39.04 million...

Via Benzinga

Topics Earnings

Why Global Blood Therapeutics Stock Is Sinking Today ↗

May 06, 2021

The company reported disappointing sales for its sickle-cell disease drug.

Via The Motley Fool

Global Blood Therapeutics (GBT) Q1 2021 Earnings Call Transcript ↗

May 06, 2021

GBT earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

A Peek Into The Markets: US Stock Futures Edge Higher; Bank Earnings In Focus ↗

April 14, 2021

Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the Nasdaq jumped over 1% in the previous session. Investors are awaiting earnings...

Via Benzinga

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts ↗

May 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗

May 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...

Via Benzinga

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗

May 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2021 ↗

April 14, 2021

Upgrades For Cardlytics Inc (NASDAQ:CDLX), Craig-Hallum upgraded the previous rating of Hold to Buy. For the fourth quarter, Cardlytics had an EPS of $0.05, compared to...

Via Benzinga

Global Blood Therapeutics' Sickle Cell Med Results In Rapid, Durable Improvements In Hemoglobin Levels Throughout 72 Weeks Of Treatment ↗

April 08, 2021

Global Blood Therapeutics Inc (NASDAQ: GBT) has announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.